MERGERS, ACQUISITIONS & ASSET SALES |
Acquiring Company |
Target(s) |
Deal Summary |
Invitae |
Singular Bio |
- Price: $55 million—approximately 2.5 million shares of Invitae common stock + $5.7 million in cash
- Status: Expected to close in July or August
- Singular employees that stay with company to get up to $90 million in Invitae contingent stock awards
- Acquisition of firm specializing in single-molecule, cell-free DNA analysis for non-invasive prenatal testing advances Invitae's strategy to push into NIPT space
|
Ascenda Biosciences |
Provista Diagnostics |
- Price: Undisclosed
- Status: Closed
- Acquisition of proteomic diagnostic firm which produces Videssa Breast test assessing whether women with indeterminate mammograms need a biopsy
|
BioMérieux |
Suzhou Hybiome Biomedical Engineering |
- Price: Undisclosed
- Status: Closed
- BioMérieux increases its equity holdings in Chinese immunoassay producer in which it acquired majority stake in 2018 from 54% to 67%
|
Thermo Fisher Scientific |
HighChem |
- Price: Undisclosed
- Status: Closed
- Slovakia-based developer of mass spectrometry software to be integrated into Thermo Fisher's chromatography and mass spectrometry business
|
Covance Drug Development (Lab Corp) |
Envigo |
- Price: $485 million
- Status: No closing date announced
- Covance acquires Envigo's nonclinical researcher services while Envigo's Research Models Services business acquires LabCorp's Covance Research Products business
|
Bio-Techne |
B-MoGen Biotechnologies |
- Price: Purchase of 100% of B-Mogen stock financed with cash on hand for undisclosed price
- Status: Closed
- Bio-Techne to include B-MoGen's technology in its own cell and gene therapy products
|
Meridian Bioscience |
GenePOC |
- Price: $50 million + up to $70 million more in contingent milestone payments
- Status: Closing of deal announced in April
Acquisition of Quebec City-based molecular diagnostics firm |
Beckman Coulter Life Sciences |
Cytobank |
- Price: Undisclosed
- Status: Closed
- Acquisition of single-cell data analysis and software-as-a-service company enables allows Beckman Coulter to offer a high-end data analytics solution for pharma/biopharma and academic research
|
Lumos Diagnostics |
RPS Diagnostics |
- Price: Undisclosed
- Status: Closed
- Merged company to keep Lumos name and focus on international launch of RPS' FebriDx blood-based POC test for identifying febrile acute respiratory infections (ARI) and differentiating viral and bacterial infections
|
Schott |
Minifab |
- Price: Undisclosed
- Status: Expected to close in 2019
- German producer of glass substrates for microarrays and microfluidic components made of glass acquires Australian microfluidics company
- Combined firms to create centers of excellence for polymer in Australia and glass in Germany
|
PerkinElmer |
Cisbio Bioassays |
- Price: $219.8 million
- Status: Closed
- PerkinElmer acquires life sciences + DX kits and reagents manufacturer with $50 million in 2018 revenues
|
Todos Medical |
Amarantus Bioscience Holding |
- Price: Undisclosed
- Status: To close when Todos' stock is listed on a national stock exchange
- Todos exercises option to acquire remaining 80% of its Breakthrough Diagnostics joint venture with Amarantus
- Parties entered into joint venture in December 2018 to develop LymPro, a blood-based lymphocyte proliferation assay, as diagnostic test for Alzheimer's
|
Constellation Alpha Capital |
DermTech |
- Price: Undisclosed price paid in Constellation stock shares
- Status: Closed
- Under merger terms, skin cancer diagnostics firm to become wholly owned subsidiary of Constellation
|
Erasmus University Medical Center |
GenomeScan |
- Price: Undisclosed
- Status: Closed
- Erasmus MC acquires undisclosed number of shares in genomics service provider
- Both parties to collaborate with Leiden University Medical Center (LUMC), an existing GenomeScan shareholder, in molecular diagnostics and research
|
STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS |
Partner 1 |
Partner(s) 2+ |
Deal Summary |
Thermo Fisher Scientific |
Predictive Laboratories |
- Objective: Female infertility research
- Dynamic: Predictive Labs to implement Thermo Fisher reproductive health tests, including Applied Biosystems CarrierScan assay, Ion ReproSeq PGS assay, CytoScan Dx assay and Ion AmpliSeq Exome RDY for whole-exome sequencing
|
Thermo Fisher Scientific |
Newomics |
- Objective: Develop new microflow LC-MS workflows for validating disease biomarkers
- Dynamic: Combine Thermo Fisher's microflow LC-MS systems and Nanospray Flex ion source with Newomics' multi-nozzle emitters
|
Thermo Fisher Scientific |
Evosep |
- Objective: Develop high-throughput clinical research proteomics workflows for profiling large plasma sample cohorts
- Dynamic: Combine the Thermo Scientific Q Exactive HF-X mass spectrometer and the Evosep One liquid chromatography solution to develop standardized and high-throughput analytical protocols for proteomics, translational research and pharmaceutical applications
|
Thermo Fisher Scientific |
Biognosys |
- Objective: Develop data-independent acquisition (DIA) mass spectrometry-based workflows for quantification of target proteins in plasma and other body fluids
- Dynamic: Extend existing collaboration aimed at developing methods for analyzing plasma and other body fluids
|
Qiagen |
DiaSorin |
- Objective: Develop ultra-sensitive in vitro test for Lyme disease
- Dynamic: Test to combine Qiagen's QuantiFeron (interferon-gamma release assay) technology with DiaSorin's Liaison automated analyzers
- Companies plan to market assay for use alongside DiaSorin's existing Lyme disease tests, Liaison Borrelia IgG and IgM
- Companies also plan to run multi-site clinical validations during 2020 Lyme disease season and apply for regulatory approval in US and Europe later that year
|
Resolution Bioscience |
Janssen Pharmaceuticals |
- Objective: Develop Resolution's HRD liquid biopsy test as companion diagnostic for niraparib, a PARP inhibitor being investigated to treat patients with metastatic castration-resistant prostate cancer
- Dynamic: Resolution HRD is a blood-based, cell-free DNA assay that detects single nucleotide variants, copy number variants, and deletions in genes related to homologous recombination deficiency (HRD)
- If approved, new CDx assay would be first test to find gene deletions from cfDNA and distinguish between single copy and homozygous gene deletions through a blood draw
|
Caris Life Sciences |
Debiopharm International |
- Objective: Develop companion diagnostic for new oncology drug being developed by Debiopharm
- Dynamic: Use Caris' Molecular Intelligence (MI) Transcriptome assay for mRNA analysis to detect rare fibroblast growth factor receptor (FGFR) fusions and identify eligible patients for Debiopharm's FUZE phase II clinical trial of Debio 1347, a selective FGFR inhibitor
|
Foundation Medicine |
Bayer |
- Objective: Develop NGS companion diagnostics
- Dynamic: Strategic global collaboration initially focusing on creating a test to identify patients eligible for treatment with larotrectinib (Vitrakvi), a TRK inhibitor approved in the US for patients with NTRK fusions regardless of tumor type or location
|
Mayo Clinic |
Regeneron Pharmaceuticals |
- Objective: Sequence the exomes and genotype 100,000 patient DNA samples from Mayo's biobank
- Dynamic: Regeneron to pay for the sequencing and genotyping
- Both partners to have access to the data for research purposes
|
University of California |
GlaxoSmithKline |
- Objective: Establish Laboratory for Genomics Research (LGR) to investigate disease-causing gene mutations and develop new technologies using CRISPR to accelerate discovery of new drugs
- Dynamic: Five-year collaboration in which GSK to provide up to $67 million in funding, facilities for 24 full-time university employees and up to 14 full-time GSK employees
- Initial focus on immunology, oncology and neuroscience
|
GeneNews |
Oncore Pharma |
- Objective: Commercialize GeneNews ColonSentry test in all countries outside US and Canada—specifically, deploy 1.75 million ColonSentry tests in next five years
- Dynamic: Five-year exclusive licensing and services deal under which GeneNews to receive a fixed fee per test, a special royalty payment equal to 10% of Oncore's yearly profits and 1 million shares of Oncore stock
- All ColonSentry tests to be processed in GeneNews' Virginia laboratory
- Initial focus on Netherlands, Belgium, Luxembourg, Germany, France, Switzerland, Austria, Spain, Monaco, Italy, Portugal, UK, Ireland, Norway, Sweden, Finland, Denmark, Israel and UAE
|
LabCorp |
Mount Sinai Health System |
- Objective: Establish the Mount Sinai Digital and Artificial Intelligence-Enabled Pathology Center of Excellence
- Dynamic: To achieve integration, Mount Sinai to implement Philips' IntelliSite Pathology Solution, which LabCorp is in the process of implementing at its own labs
- Center of Excellence, to be housed within Mount Sinai's Department of Pathology, Molecular and Cell-Based Medicine, to begin by using new digital pathology tools for interpretation of genitourinary cancers, primarily prostate tumors and head and neck cancers
|
Sanford Health |
Harvard Medical School + Brigham and Women's Hospital |
- Objective: Determine best practices for using genetic screening to improve population health
- Dynamic: Four-year collaboration with experts in genomic medicine from Harvard and Brigham and Women's to help guide Sanford researchers use and interpret data collected via Sanford Chip, a new $49 pharmacogenomic laboratory developed test to identify genetic risk factors for medication use and prescription
|
Decode Genetics |
Intermountain Healthcare |
- Objective: Genetics research
- Dynamic: Partners to perform whole-genome sequencing on 500,000 patients in Utah and Idaho in a population health initiative called HerediGene
|
Cartana |
Lunaphore Technologies |
- Objective: Develop hardware for automated sequencing and imaging cycles
- Dynamic: Integrate Cartana's in situ RNA sequencing (ISS) technology with Lunaphore's microfluidic tissue processor technology
|
Hamilton |
Enable Biosciences |
- Objective: Fully automate the processing of Enable's ultra-sensitive immunoassay technology in a hands-free workflow with Hamilton's automated workstation
- Dynamic: Firms to automate the processing of up to 96 liquid biopsy samples at one time using Enable Bio's Antibody Detection by Agglutination PCR (ADAP) technology for immunoassays
|
NuView Life Sciences |
Aperture Bio |
- Objective: Evaluate NuView's NV-VPAC1 urogenital cancer test
- Dynamic: Companies to assess use of the test on Aperture's automated RAPID-B platform, which uses robotic flow cytometry to identify and count targeted cellular material in body fluids
|
Owlstone Medical |
International Association of Heat and Frost Insulators and Allied Workers (IAHFIAW) |
- Objective: Identify and verify breath-based biomarkers for early detection of malignant mesothelioma, an asbestos-caused disorder common in construction and other union workers
- Dynamic: Use Owlstone's Breath method to measure volatile organic compounds (VOCs) in breath
- Three-year project with phase 1 to focus on identifying VOCs in breath of people diagnosed with malignant mesothelioma, and phase 2 to launch a blind study to verify the sensitivity, specificity and positive and negative predictive values of selected VOC biomarkers identified in phase 1
|
Biocartis |
Kite (Gilead Sciences) |
- Objective: Develop molecular-based assays supporting Kite's therapies on Biocartis' Idylla platform
- Dynamic: Collaboration part of Biocartis' ongoing strategy of expanding its presence in the oncology market via a series of immunotherapy and liquid biopsy assays on the Idylla platform
|
Biotage |
Shandong Yingsheng Biotechnology |
- Objective: Develop clinical mass spectrometry applications for China market
- Dynamic: Biotage to provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand together with Yingsheng's other products
|
Mobidiag |
Autobio Diagnostics |
- Objective: Develop observational research analytics tools to assess treatment outcomes for precision oncology
- Dynamic: New Automobi Molecular Diagnostics joint venture to seek Chinese regulatory approval for Novodiag platform and assays and establish local facilities to manufacture system parts and disposables
- Autobio has invested €8 million and holds a 65% stake in the venture; Mobidiag owns the remaining 35% under a €4.3 million investment
- Autobio has also made a €10 million equity investment in Mobidiag itself
|
Bruker |
PreOmics |
- Objective: Commercialize consumables and software for Bruker's 4D Proteomics technology
- Dynamic: Codevelopment and comarketing agreement covering PreOmics' inStageTip (iST) sample prep technology on Bruker's TimsTOF Pro
|
Bruker |
Genedata |
- Objective: Develop NGS host cell protein analysis platform
- Dynamic: Make Genedata's Expressionist software platform support Bruker's TimsTOF Pro 4D omics format
|
Invitae |
Horizon Therapeutics |
- Objective: Support Invitae's urea cycle disorder genetic (UCD) testing program
- Dynamic: Invitae to perform genetic testing and Horizon to provide unspecified financial support for program aimed at improving diagnosis of UCD
|
Luminex |
EDP Biotech |
- Objective: Develop and commercialize blood-based colorectal test using Luminex's xMAP technology
- Dynamic: Test, called ColoPlex, uses multiplexed immunoassay technology and machine learning to detect early state colorectal cancer and precancerous polyps
|
DISTRIBUTION, SALES & MARKETING AGREEMENTS |
Property Owner |
Distributor |
Deal Summary |
Parallex BioAssays |
Bioké |
- Products: Parallex BioAssays' SnapChip microarray products
- Territory: Belgium, Netherlands, Luxembourg
|
Patia |
Premier Medical Laboratory Services |
- Products: Patia's type 2 diabetes risk assay DIABETESpredict which combines genetic risk analysis with behavioral and lifestyle assessments
- Territory: US
- Exclusive
|
Biomerica |
Maxhealth |
- Products: Biomerica's EZ Detect colorectal cancer screening test
- Territory: China
- Exclusive
- Maxhealth agrees to meet annual minimum purchase requirements totalling $17 million over seven years and pay Biomerica $1 million upfront upon meeting certain undisclosed conditions
|
LICENSES |
Licensor |
Licensee |
Deal Summary |
ERS Genomics |
Bioneer |
- Property: CRISPR-Cas9 genome editing technology
- Bioneer gets right to use technology to develop and commercialize CRISPR-edited cell-based disease models
|
Integrated DNA Technologies |
Editas Medicine |
- Property: Newly released CRISPR Alt-R Cas12a (Cpf1) enzyme for human therapeutic applications
- Exclusive
|
SUPPLY, SERVICE & TESTING AGREEMENTS |
Supplier/Servicer |
Client/User |
Deal Summary |
Agilent Technologies |
SomaLogic |
- Multi-year supply agreement for Agilent to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay
|
NEW CLINICAL STUDIES |
DX Partner |
Other Partner(s) |
Description of Study |
BrainBox Solutions |
None |
- HeadSMART (Head injury Serum markers and Multimodalities for Assessing Response to Trauma) to support regulatory filings for marketing approval of the TBI test
|